These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

338 related articles for article (PubMed ID: 27222056)

  • 1. Topical Use of Mammalian Target of Rapamycin (mTOR) Inhibitors in Tuberous Sclerosis Complex-A Comprehensive Review of the Literature.
    Jóźwiak S; Sadowski K; Kotulska K; Schwartz RA
    Pediatr Neurol; 2016 Aug; 61():21-7. PubMed ID: 27222056
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Topical use of mammalian target of rapamycin inhibitors in dermatology: A systematic review with meta-analysis.
    Leducq S; Giraudeau B; Tavernier E; Maruani A
    J Am Acad Dermatol; 2019 Mar; 80(3):735-742. PubMed ID: 30744877
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systemic effects of treatment with mTOR inhibitors in tuberous sclerosis complex: a comprehensive review.
    Sadowski K; Kotulska K; Schwartz RA; Jóźwiak S
    J Eur Acad Dermatol Venereol; 2016 Apr; 30(4):586-94. PubMed ID: 26403211
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of mTOR inhibitors (rapalogs) for the treatment of skin changes in tuberous sclerosis complex.
    Farges D; Sigg N; Ville D; Martin L
    Arch Pediatr; 2022 Dec; 29(5S):5S20-5S24. PubMed ID: 36585067
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical and Histologic Analysis of the Efficacy of Topical Rapamycin Therapy Against Hypomelanotic Macules in Tuberous Sclerosis Complex.
    Wataya-Kaneda M; Tanaka M; Yang L; Yang F; Tsuruta D; Nakamura A; Matsumoto S; Hamasaki T; Tanemura A; Katayama I
    JAMA Dermatol; 2015 Jul; 151(7):722-30. PubMed ID: 25692384
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanistic target of rapamycin (mTOR) in tuberous sclerosis complex-associated epilepsy.
    Curatolo P
    Pediatr Neurol; 2015 Mar; 52(3):281-9. PubMed ID: 25591831
    [TBL] [Abstract][Full Text] [Related]  

  • 7. mTOR inhibitors in the pharmacologic management of tuberous sclerosis complex and their potential role in other rare neurodevelopmental disorders.
    Franz DN; Capal JK
    Orphanet J Rare Dis; 2017 Mar; 12(1):51. PubMed ID: 28288694
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Topical everolimus for facial angiofibromas in the tuberous sclerosis complex. A first case report.
    Dill PE; De Bernardis G; Weber P; Lösch U
    Pediatr Neurol; 2014 Jul; 51(1):109-13. PubMed ID: 24810875
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic targeting of mTOR in tuberous sclerosis.
    Sampson JR
    Biochem Soc Trans; 2009 Feb; 37(Pt 1):259-64. PubMed ID: 19143643
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mammalian Target of Rapamycin Inhibitors and Life-Threatening Conditions in Tuberous Sclerosis Complex.
    Moavero R; Romagnoli G; Graziola F; Curatolo P
    Semin Pediatr Neurol; 2015 Dec; 22(4):282-94. PubMed ID: 26706015
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety considerations of mammalian target of rapamycin inhibitors in tuberous sclerosis complex and renal transplantation.
    Somers MJ; Paul E
    J Clin Pharmacol; 2015 Apr; 55(4):368-76. PubMed ID: 25402866
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of Renal Angiomyolipoma and Other Hamartomas in Patients with Tuberous Sclerosis Complex.
    Samuels JA
    Clin J Am Soc Nephrol; 2017 Jul; 12(7):1196-1202. PubMed ID: 28302901
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Role of mTOR Inhibitors in the Treatment of Patients with Tuberous Sclerosis Complex: Evidence-based and Expert Opinions.
    Curatolo P; Bjørnvold M; Dill PE; Ferreira JC; Feucht M; Hertzberg C; Jansen A; Jóźwiak S; Kingswood JC; Kotulska K; Macaya A; Moavero R; Nabbout R; Zonnenberg BA
    Drugs; 2016 Apr; 76(5):551-65. PubMed ID: 26927950
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management of side effects of mTOR inhibitors in tuberous sclerosis patients.
    Sadowski K; Kotulska K; Jóźwiak S
    Pharmacol Rep; 2016 Jun; 68(3):536-42. PubMed ID: 26891243
    [TBL] [Abstract][Full Text] [Related]  

  • 15. mTOR inhibitor therapy as a disease modifying therapy for tuberous sclerosis complex.
    Franz DN; Krueger DA
    Am J Med Genet C Semin Med Genet; 2018 Sep; 178(3):365-373. PubMed ID: 30307123
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differentiating the mTOR inhibitors everolimus and sirolimus in the treatment of tuberous sclerosis complex.
    MacKeigan JP; Krueger DA
    Neuro Oncol; 2015 Dec; 17(12):1550-9. PubMed ID: 26289591
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Everolimus: an mTOR inhibitor for the treatment of tuberous sclerosis.
    Franz DN
    Expert Rev Anticancer Ther; 2011 Aug; 11(8):1181-92. PubMed ID: 21916571
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and Safety of Topical Rapamycin in Patients With Facial Angiofibromas Secondary to Tuberous Sclerosis Complex: The TREATMENT Randomized Clinical Trial.
    Koenig MK; Bell CS; Hebert AA; Roberson J; Samuels JA; Slopis JM; Tate P; Northrup H;
    JAMA Dermatol; 2018 Jul; 154(7):773-780. PubMed ID: 29800048
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of current data on the use of topical mTOR inhibitors in the treatment of facial angiofibromas in tuberous sclerosis complex-An update.
    Balestri R; Rizzoli L; Pedrolli A; Urru SAM; Rech G; Neri I; Girardelli CR; Magnano M
    J Eur Acad Dermatol Venereol; 2023 Mar; 37(3):474-487. PubMed ID: 36300771
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization and management of facial angiofibroma related to tuberous sclerosis complex in the United States: retrospective analysis of the natural history database.
    Boggarapu S; Roberds SL; Nakagawa J; Beresford E
    Orphanet J Rare Dis; 2022 Sep; 17(1):355. PubMed ID: 36104799
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.